NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $8,023,000 | -33.3% | 60,700 | -12.7% | 0.07% | -29.6% |
| Q4 2020 | $12,026,000 | -23.9% | 69,500 | -51.1% | 0.10% | -33.8% |
| Q3 2020 | $15,806,000 | +21.2% | 142,000 | -35.4% | 0.15% | +19.4% |
| Q2 2020 | $13,040,000 | +3.6% | 219,900 | +17.7% | 0.12% | -17.3% |
| Q1 2020 | $12,586,000 | -63.7% | 186,900 | -54.6% | 0.15% | -51.5% |
| Q4 2019 | $34,719,000 | -4.7% | 412,000 | -15.4% | 0.31% | -4.0% |
| Q3 2019 | $36,418,000 | -35.3% | 487,000 | -45.3% | 0.32% | -25.6% |
| Q2 2019 | $56,276,000 | +18.2% | 890,015 | -10.0% | 0.43% | +18.0% |
| Q1 2019 | $47,611,000 | +11.0% | 988,390 | -22.9% | 0.37% | -0.8% |
| Q4 2018 | $42,910,000 | -30.8% | 1,281,675 | +8.4% | 0.37% | -10.0% |
| Q3 2018 | $61,964,000 | +33.2% | 1,182,525 | -20.4% | 0.41% | +32.2% |
| Q2 2018 | $46,509,000 | – | 1,485,900 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |